Details of Drug-Metabolizing Enzyme (DME)

General Information of Drug-Metabolizing Enzyme (DME) (ID: DENP5RY)

DME Name Quinone reductase 1 (NQO1)
Synonyms Menadione reductase; NAD(P)H dehydrogenase [quinone] 1; Azoreductase; DT-diaphorase; NAD(P)H:quinone oxidoreductase 1; Phylloquinone reductase; DIA4; DTD; QR1; NMOR1; NQO1
Gene Name NQO1
UniProt ID
NQO1_HUMAN
INTEDE ID
DME0097
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Gene ID
1728
EC Number EC: 1.6.5.2
Oxidoreductase
NADH/NADPH oxidoreductase
Quinone acceptor oxidoreductase
EC: 1.6.5.2
Lineage Species: Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Sequence
MVGRRALIVLAHSERTSFNYAMKEAAAAALKKKGWEVVESDLYAMNFNPIISRKDITGKL
KDPANFQYPAESVLAYKEGHLSPDIVAEQKKLEAADLVIFQFPLQWFGVPAILKGWFERV
FIGEFAYTYAAMYDKGPFRSKKAVLSITTGGSGSMYSLQGIHGDMNVILWPIQSGILHFC
GFQVLEPQLTYSIGHTPADARIQILEGWKKRLENIWDETPLYFAPSSLFDLNFQAGFLMK
KEVQDEEKNKKFGLSVGHHLGKSIPTDNQIKARK
Function This enzyme serves as a quinone reductase in connection with conjugation reactions of hydroquinons involved in detoxification pathways.
KEGG Pathway
Fluid shear stress and atherosclerosis (hsa05418 )
Hepatocellular carcinoma (hsa05225 )
Metabolic pathways (hsa01100 )
Pathways in cancer (hsa05200 )
Ubiquinone and other terpenoid-quinone biosynthesis (hsa00130 )
Reactome Pathway
Regulation of ornithine decarboxylase (ODC) (R-HSA-350562 )

Molecular Interaction Atlas (MIA) of This DME

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DME
4 Approved Drug(s) Metabolized by This DME
Drug Name Drug ID Indication ICD 11 Highest Status REF
Carboplatin DMG281S Adenocarcinoma 2D40 Approved [10]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [10]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [11]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [10]
1 Clinical Trial Drug(s) Metabolized by This DME
Drug Name Drug ID Indication ICD 11 Highest Status REF
Beta-Lapachone DMMI84K Solid tumour/cancer 2A00-2F9Z Phase 2 [12]
1 Discontinued Drug(s) Metabolized by This DME
Drug Name Drug ID Indication ICD 11 Highest Status REF
CB1954 DMVP4YK Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [13]
1 Investigative Drug(s) Metabolized by This DME
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nitrobenzanthrone DMN6L70 N. A. N. A. Investigative [14]

Molecular Expression Atlas (MEA) of This DME

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DME
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Acute myelocytic leukaemia 2B33.1 Bone marrow 1.17E-30 3.16E-01 1.31E+00
Alopecia ED70 Skin from scalp 4.31E-02 -1.22E-01 -2.12E-01
Alzheimer's disease 8A20 Entorhinal cortex 3.16E-02 2.60E-01 3.13E-01
Ankylosing spondylitis FA92.0 Pheripheral blood 1.39E-01 4.26E-01 8.23E-01
Aortic stenosis BB70 Calcified aortic valve 7.08E-02 -1.06E+00 -1.04E+00
Apnea 7A40 Hyperplastic tonsil 1.40E-01 -2.21E+00 -2.32E+00
Arthropathy FA00-FA5Z Peripheral blood 6.38E-01 3.78E-02 1.94E-01
Asthma CA23 Nasal and bronchial airway 8.60E-08 7.56E-01 6.50E-01
Atopic dermatitis EA80 Skin 8.24E-01 -1.24E-01 -3.51E-01
Autism 6A02 Whole blood 9.09E-01 -4.12E-02 -2.10E-01
Autoimmune uveitis 9A96 Peripheral monocyte 1.69E-02 -2.43E-01 -6.52E-01
Autosomal dominant monocytopenia 4B04 Whole blood 6.66E-02 1.11E-01 6.64E-01
Bacterial infection of gingival 1C1H Gingival tissue 9.23E-10 -5.99E-01 -1.10E+00
Batten disease 5C56.1 Whole blood 3.19E-01 1.45E-01 9.53E-01
Behcet's disease 4A62 Peripheral blood 7.65E-01 1.13E-03 5.58E-03
Bipolar disorder 6A60-6A6Z Prefrontal cortex 2.38E-02 2.13E-01 8.15E-01
Bladder cancer 2C94 Bladder tissue 2.05E-04 8.91E-01 2.67E+00
Breast cancer 2C60-2C6Z Breast tissue 3.77E-03 4.72E-01 4.14E-01
Cardioembolic stroke 8B11.20 Whole blood 1.22E-02 2.71E-01 7.15E-01
Cervical cancer 2C77 Cervical tissue 8.92E-01 -7.74E-02 -1.17E-01
Childhood onset rheumatic disease FA20.Z Peripheral blood 6.17E-01 -4.06E-02 -2.70E-01
Chronic hepatitis C 1E51.1 Whole blood 1.93E-01 -1.70E-01 -1.26E+00
Chronic obstructive pulmonary disease CA22 Lung tissue 4.98E-03 2.34E-01 4.32E-01
Chronic obstructive pulmonary disease CA22 Small airway epithelium 1.73E-05 8.20E-01 8.68E-01
Chronic rhinosinusitis CA0A Sinus mucosa tissue 4.40E-01 -3.14E-01 -3.53E-01
Colon cancer 2B90 Colon tissue 4.53E-18 8.63E-01 1.19E+00
Coronary artery disease BA80-BA8Z Peripheral blood 9.25E-01 -4.59E-02 -1.45E-01
Diffuse large B-cell lymphoma 2A81 Tonsil tissue 7.55E-01 1.37E-01 1.20E-01
Endometriosis GA10 Endometrium tissue 5.15E-01 -4.28E-01 -2.94E-01
Familial hypercholesterolemia 5C80.00 Peripheral blood 6.10E-01 9.50E-03 4.66E-02
Familial hypercholesterolemia 5C80.00 Whole blood 8.03E-02 1.78E-01 6.65E-01
Gastric cancer 2B72 Gastric tissue 8.24E-01 -2.93E-01 -1.46E-01
Glioblastopma 2A00.00 Nervous tissue 8.07E-01 5.26E-02 6.48E-02
Glioma 2A00.0Y-2A00.0Z Brain stem tissue 1.43E-01 -2.23E+00 -2.95E+00
Glioma 2A00.0Y-2A00.0Z White matter tissue 7.08E-03 1.14E+00 9.94E-01
Head and neck cancer 2D42 Head and neck tissue 1.91E-07 -9.82E-01 -6.85E-01
HIV-associated neurocognitive impairment 8A2Y-8A2Z White matter tissue 8.37E-01 -2.96E-02 -4.29E-02
Huntington's disease 8A01.10 Whole blood 3.38E-01 -8.26E-02 -3.63E-01
Idiopathic pulmonary fibrosis CB03.4 Lung tissue 4.14E-01 -2.42E-01 -3.87E-01
Immunodeficiency 4A00-4A20 Peripheral blood 6.52E-04 4.19E-01 2.25E+00
Influenza 1E30 Whole blood 5.97E-03 -6.88E-01 -2.88E+00
Interstitial cystitis GC00.3 Bladder tissue 4.38E-02 -1.31E-01 -4.16E-01
Intracranial aneurysm 8B01.0 Intracranial artery 4.16E-02 4.12E-01 1.21E+00
Irritable bowel syndrome DD91.0 Rectal colon tissue 7.71E-02 -2.24E-01 -4.07E-01
Ischemic stroke 8B11 Peripheral blood 1.24E-01 -1.46E-01 -6.65E-01
Juvenile idiopathic arthritis FA24 Peripheral blood 2.11E-02 -1.58E-01 -4.04E-01
Lateral sclerosis 8B60.4 Skin 1.33E-01 4.84E-01 9.25E-01
Lateral sclerosis 8B60.4 Cervical spinal cord 5.81E-02 5.09E-01 1.61E+00
Liver cancer 2C12.0 Liver tissue 9.60E-52 1.24E+00 4.48E+00
Liver failure DB99.7-DB99.8 Liver tissue 6.27E-03 3.49E+00 1.22E+01
Lung cancer 2C25 Lung tissue 6.02E-66 1.67E+00 2.21E+00
Lupus erythematosus 4A40 Whole blood 1.85E-01 6.44E-02 1.17E-01
Major depressive disorder 6A70-6A7Z Hippocampus 7.92E-01 2.15E-02 8.04E-02
Major depressive disorder 6A70-6A7Z Whole blood 1.16E-01 -1.47E-01 -3.90E-01
Melanoma 2C30 Skin 7.59E-01 1.03E-01 5.78E-02
Multiple myeloma 2A83.1 Peripheral blood 7.54E-01 -3.18E-01 -2.11E-01
Multiple myeloma 2A83.1 Bone marrow 2.00E-02 2.24E-01 8.77E-01
Multiple sclerosis 8A40 Plasmacytoid dendritic cells 3.23E-01 5.19E-02 2.90E-01
Myelodysplastic syndrome 2A36-2A3Z Bone marrow 1.51E-02 8.57E-02 2.12E-01
Myelofibrosis 2A20.2 Whole blood 7.39E-01 5.41E-02 3.03E-01
Myocardial infarction BA41-BA50 Peripheral blood 2.59E-03 -3.25E-01 -4.39E-01
Myopathy 8C70.6 Muscle tissue 3.93E-04 7.59E-01 2.15E+00
Neonatal sepsis KA60 Whole blood 2.60E-01 -8.98E-04 -3.02E-03
Neuroectodermal tumour 2A00.11 Brain stem tissue 6.47E-04 -7.13E-01 -1.75E+00
Non-alcoholic fatty liver disease DB92 Liver tissue 8.30E-01 -4.62E-03 -3.38E-02
Obesity related type 2 diabetes 5A11 Omental adipose tissue 5.80E-01 2.74E-01 2.73E-01
Olive pollen allergy CA08.00 Peripheral blood 8.58E-01 1.35E-01 1.16E-01
Oral cancer 2B6E Oral tissue 4.23E-01 -5.85E-02 -5.42E-02
Osteoarthritis FA00-FA0Z Synovial tissue 5.37E-01 1.91E-01 6.74E-02
Osteoporosis FB83.1 Bone marrow 2.14E-02 -6.71E-01 -1.37E+00
Ovarian cancer 2C73 Ovarian tissue 7.99E-05 1.85E+00 2.27E+00
Pancreatic cancer 2C10 Pancreas 8.89E-07 3.64E+00 2.56E+00
Parkinson's disease 8A00.0 Substantia nigra tissue 3.53E-01 2.12E-01 3.98E-01
Pediatric respiratory syncytial virus infection CA40.11 Peripheral blood 8.75E-01 -4.16E-02 -2.06E-01
Pituitary cancer 2D12 Pituitary tissue 2.49E-01 1.86E-01 2.76E-01
Pituitary gonadotrope tumour 2D12 Pituitary tissue 5.72E-01 1.85E-01 2.39E-01
Polycystic ovary syndrome 5A80.1 Vastus lateralis muscle 2.89E-01 -1.31E-01 -7.52E-01
Polycythemia vera 2A20.4 Whole blood 1.56E-03 1.70E-01 7.18E-01
Pompe disease 5C51.3 Biceps muscle 2.98E-07 2.84E+00 4.10E+00
Preterm birth KA21.4Z Myometrium 2.14E-02 1.26E+00 4.77E+00
Prostate cancer 2C82 Prostate 7.43E-01 2.03E-01 3.79E-01
Psoriasis EA90 Skin 3.64E-01 1.28E-01 2.20E-01
Rectal cancer 2B92 Rectal colon tissue 2.61E-03 9.68E-01 2.40E+00
Renal cancer 2C90-2C91 Kidney 4.26E-01 2.84E-01 3.53E-01
Retinoblastoma 2D02.2 Uvea 1.97E-05 2.00E+00 7.69E+00
Rheumatoid arthritis FA20 Synovial tissue 3.48E-04 5.07E-01 9.46E-01
Rhinovirus infection CA42.1 Nasal epithelium tissue 1.24E-02 -8.30E-02 -3.02E-01
Schizophrenia 6A20 Prefrontal cortex 9.71E-01 -3.49E-02 -4.68E-02
Schizophrenia 6A20 Superior temporal cortex 8.39E-01 1.59E-01 2.15E-01
Scleroderma 4A42.Z Whole blood 2.27E-01 1.45E-01 7.05E-01
Seizure 8A60-8A6Z Whole blood 3.27E-01 1.90E-01 7.51E-01
Sensitive skin EK0Z Skin 7.72E-01 8.58E-02 1.90E-01
Sepsis with septic shock 1G41 Whole blood 1.47E-01 2.05E-02 6.52E-02
Shwachman-Diamond syndrome 3A70.0 Bone marrow 1.14E-01 -1.03E-01 -5.90E-01
Sickle cell disease 3A51.0-3A51.3 Peripheral blood 2.37E-01 1.33E-01 4.85E-01
Simpson golabi behmel syndrome LD2C Adipose tissue 7.79E-01 3.02E-02 4.45E-02
Sjogren's syndrome 4A43.2 Salivary gland tissue 5.31E-01 2.36E-01 1.53E+00
Skin cancer 2C30-2C3Z Skin 8.70E-33 1.17E+00 1.53E+00
Thrombocythemia 3B63 Whole blood 9.85E-01 -6.64E-02 -4.72E-01
Thrombocytopenia 3B64 Whole blood 7.19E-01 7.33E-01 9.69E-01
Thyroid cancer 2D10 Thyroid 7.42E-08 7.85E-01 1.05E+00
Tibial muscular dystrophy 8C75 Muscle tissue 3.95E-02 -6.75E-01 -1.22E+00
Tuberous sclerosis complex LD2D.2 Perituberal tissue 4.28E-01 2.80E-01 5.19E-01
Type 2 diabetes 5A11 Liver tissue 6.84E-01 -4.29E-03 -3.66E-02
Ureter cancer 2C92 Urothelium 2.67E-02 2.39E-01 1.00E+00
Uterine cancer 2C78 Endometrium tissue 1.66E-06 6.88E-01 7.41E-01
Vitiligo ED63.0 Skin 3.08E-02 -4.09E-01 -2.04E+00
------------------------------------------------------------------------------------
⏷ Show the Full List of DME Expression Under 107 Diseases

The Drug Therapeutic Target (DTT) Role of This DME

DME DTT Name Quinone reductase 1 (NQO1) DTT Info
DME DTT Type Clinical trial
3 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
ARQ 761 DMH5CAL Pancreatic cancer 2C10 Phase 2 [1]
BioE-743 DM7PT8R Leigh syndrome 5C53.24 Phase 2 [2]
Coenzyme Q10 analog DMO0VGH Huntington disease 8A01.10 Phase 2 [3]
28 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
2-Benzyl-1-hydroxy-3H-benzo[f]chromen-3-one DMV7IWE Discovery agent N.A. Investigative [4]
3-(3,4-Dimethylbenzyl)-4-hydroxy-2H-chromen-2-one DM9BYVL Discovery agent N.A. Investigative [4]
3-Benzyl-4-hydroxy-2H-benzo[h]chromen-2-one DMA5EHC Discovery agent N.A. Investigative [4]
3-Benzyl-4-hydroxy-2H-chromen-2-one DM3BFX0 Discovery agent N.A. Investigative [4]
3-Benzyl-4-hydroxy-6,7-dimethyl-2H-chromen-2-one DML0ME9 Discovery agent N.A. Investigative [4]
4-amino-2H-chromen-2-one DM3MUF1 Discovery agent N.A. Investigative [5]
4-Hydroxy-3-(1-naphthylmethyl)-2H-chromen-2-one DMY3OHK Discovery agent N.A. Investigative [4]
4-Hydroxy-3-(2-naphthylmethyl)-2H-chromen-2-one DMM3QPL Discovery agent N.A. Investigative [4]
Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone] DMVRXH3 Discovery agent N.A. Investigative [6]
Duroquinone DML7YPS Discovery agent N.A. Investigative [6]
ES-936 DMIVZ3W Discovery agent N.A. Investigative [7]
Ethyl Bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetate DMJQTIK Discovery agent N.A. Investigative [4]
Flavin-Adenine Dinucleotide DM5S4GK Discovery agent N.A. Investigative [6]
NSC-106080 DMR6P9S Discovery agent N.A. Investigative [8]
NSC-106547 DMR2DTI Discovery agent N.A. Investigative [9]
NSC-2113 DMOGV9F Discovery agent N.A. Investigative [9]
NSC-224124 DMM9PDR Discovery agent N.A. Investigative [9]
NSC-275420 DMV2D8F Discovery agent N.A. Investigative [9]
NSC-316158 DMTPRXI Discovery agent N.A. Investigative [9]
NSC-339580 DMK0H2P Discovery agent N.A. Investigative [9]
NSC-339583 DMITE1A Discovery agent N.A. Investigative [9]
NSC-354279 DMVL51I Discovery agent N.A. Investigative [9]
NSC-621351 DMFXEIK Discovery agent N.A. Investigative [8]
NSC-645808 DMMBAR3 Discovery agent N.A. Investigative [9]
NSC-645827 DMNJLW2 Discovery agent N.A. Investigative [9]
NSC-65069 DMFEGYB Discovery agent N.A. Investigative [8]
NSC-73410 DMX0VQN Discovery agent N.A. Investigative [9]
NSC-99528 DMXZAIG Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 28 Investigative Drug(s)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Therapeutic strategies for Leber's hereditary optic neuropathy: A current update. Intractable Rare Dis Res. 2013 November; 2(4): 130-135.
4 Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56.
5 Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human panc... J Med Chem. 2007 Dec 13;50(25):6316-25.
6 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7 Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) ... J Med Chem. 2007 Nov 15;50(23):5780-9.
8 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
9 In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54.
10 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
11 Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52.
12 Beta-lapachone, a modulator of NAD metabolism, prevents health declines in aged mice. PLoS One. 2012;7(10):e47122.
13 Gene Therapy of the Central Nervous System. Charter 22 - Prodrug-Activation Gene Therapy. 2006, Pages 291-301
14 Dose-dependent response to 3-nitrobenzanthrone exposure in human urothelial cancer cells. Chem Res Toxicol. 2017 Oct 16;30(10):1855-1864.